(Q24607361)

7

object named as

J Klosterkötter

0 references

author name string

F M Leweke

1

0 references

D Piomelli

2

0 references

F Pahlisch

3

0 references

D Muhl

4

0 references

C W Gerth

5

0 references

C Hoyer

6

0 references

M Hellmich

8

0 references

D Koethe

Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology

9

0 references

language of work or name

English

0 references

publication date

2012

0 references

published in

Translational Psychiatry

0 references

volume

2

0 references

issue

3

0 references

page(s)

e94

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

The orphan receptor GPR55 is a novel cannabinoid receptor

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Endocannabinoid signalling in the blood of patients with schizophrenia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

The molecular logic of endocannabinoid signalling

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis

26 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Disruption of frontal θ coherence by Δ9-tetrahydrocannabinol is associated with positive psychotic symptoms

26 May 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Treatment of schizophrenia in the 21st Century: beyond the neurotransmitter hypothesis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Reduced cortical cannabinoid 1 receptor messenger RNA and protein expression in schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Endocannabinoids and the regulation of their levels in health and disease

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Standardized remission criteria in schizophrenia.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Agonistic properties of cannabidiol at 5-HT1a receptors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Pharmacological and molecular targets in the search for novel antipsychotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Complex pharmacology of natural cannabinoids: evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain cannabinoid receptors

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Antipsychotic effect of cannabidiol.

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3316151

Psychosis reactivity to cannabis use in daily life: an experience sampling study.

30 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Inhibition of fatty-acid amide hydrolase and CB1 receptor antagonism differentially affect behavioural responses in normal and PCP-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Cannabidiol monotherapy for treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Different effects of nabilone and cannabidiol on binocular depth inversion in Man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Anandamide elevation in cerebrospinal fluid in initial prodromal states of psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Endogenous cannabinoids in patients with schizophrenia and substance use disorder during quetiapine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTP.2012.15

Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man

21 January 2018

1 reference

12 December 2020

Elevated endogenous cannabinoids in schizophrenia

1 reference

12 December 2020

Determination of anandamide and other fatty acyl ethanolamides in human serum by electrospray tandem mass spectrometry

1 reference

12 December 2020

Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor

1 reference

12 December 2020

Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group

1 reference

12 December 2020

Identifiers

DOI

10.1038/TP.2012.15

1 reference

Dimensions Publication ID

1036553011

0 references

1 reference

1 reference

PubMed publication ID

22832859

1 reference